$0.87—Stale · unknown old
NASDAQ • Last print unknown ago
$0.87—Stale · unknown old
ZIOPHARM Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly utilizing its proprietary Sleeping Beauty gene transfer technology. The company is primarily engaged in developing treatments for hematological malignancies and solid tumors, with key assets including its lead product candidate, Ad-RTS-hIL-12, currently in clinical trials.
ZIOPHARM generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development and commercialization of its therapeutic candidates. The company has no current product sales, relying instead on milestone payments and royalties from its collaborations.
Clinical trial results for lead product candidates, particularly Ad-RTS-hIL-12
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals or advancements in clinical trial phases
Market sentiment around immuno-oncology therapies
Regulatory changes affecting drug approval processes
Technological disruption in gene therapy and oncology treatments
Emergence of alternative therapies from competitors
Potential for larger pharmaceutical companies to dominate the oncology market
High cash burn rate with no current revenue generation
Dependency on external financing for ongoing clinical trials
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare services remains relatively stable regardless of economic conditions.
Minimal impact from interest rates as ZIOPHARM does not have debt and relies on equity financing; however, higher rates could affect the valuation multiples of biotech stocks.
minimal
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock exhibits high volatility due to its reliance on clinical trial outcomes and market sentiment.